Llwytho...
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute to a broader understanding of the role and use of i...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncoimmunology |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6791446/ https://ncbi.nlm.nih.gov/pubmed/31646092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1644109 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|